| Name | Title | Contact Details |
|---|---|---|
Julie Tran |
Executive Director of Human Resources, Americas and Global Talent Development and Staffing | Profile |
Micronics is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Loxo Oncology is committed to the discovery, development, and commercialization of targeted cancer therapies with best-in-class potential. Our diverse pipeline reflects the convergence of proven therapeutic technologies with emerging insights into the underlying susceptibilities of cancer and drug resistance. It is an exciting time to develop cancer drugs. Diagnostic methods are yielding strong clues about which cancer features are actionable, “driver alterations,” in contrast to those merely along for the ride as “passenger alterations.” In the last five years, these insights have transformed the standard of care in melanoma, lung cancer and other cancers. Picking a target is just the first step in building a cancer drug. Good chemists build good drugs. The physical properties of a compound have much to do with its ultimate success or failure. Is it stable? Is it soluble? Is it absorbed? Does it reach its target? Does it engage the target? Does it cause toxicity elsewhere in the body before it achieves maximum efficacy in the cancer? In our opinion, drugs that achieve excellent exposure in the body and are highly specific for their intended targets have the highest chances of success. Once an attractive target is selected and a drug with best-in-class properties is constructed, setting up the right clinical development plan is of utmost importance. Our goal is to generate a clinical path that reflects the underlying scientific hypothesis that made the drug interesting in the first place. This often means developing the drug in a population of patients whose tumors possess a specific vulnerability targeted by the drug. Loxo Oncology was built around a team of full-time professionals and engaged scientific advisors who are aligned in choosing the most actionable targets, and pursuing them through disciplined clinical trial approaches. Our license and collaboration agreement with Array Biopharma and our experienced team allow us to construct drugs with best-in-class properties from the ground up.
Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.
Neurotrack is a digital health company dedicated to the development of non-invasive cognitive health assessment tools that will enable earlier and more effective evaluation of patients who may be at risk for cognitive decline, and help advance research of treatments for cognitive diseases, including Alzheimer`s.
JSR Life Sciences is a business unit of JSR Corporation, a global company built on more than 50 years of performance material expertise and it began research in the life sciences field more than 30 years ago. We are continually developing highly functional materials and products to meet the current and future needs of the growing biotechnology industry. Using a variety of integrated, leading-edge technologies, JSR Life Sciences provides materials that contribute to the manufacturing process of biopharmaceuticals, life science research applications, in vitro diagnostics and medical devices. JSR Life Sciences has offices, laboratories and manufacturing facilities in Tokyo and Tsukuba (JP), Sunnyvale (CA, USA), Leuven (BE) and Beijng (CN). We are a part of the JSR Corporation, an international company employing over 6’000 people worldwide and being a leading materials supplier in a variety of technology driven markets. JSR Corporation`s global network is headquartered in Tokyo (Japan) and has factories and offices all over the world. As a research-oriented organization, JSR Corporation pursues close collaborations with leading innovators in a number of industries that are key to the present and future welfare of human society: life sciences, elastomers, electronic materials, energy storage, display materials and optical materials.